Correction

This article refers to:

The use of CrossMAb technology for the generation of bi- and multispecific antibodies

Article title: The use of CrossMAb technology for the generation of bi- and multispecific antibodies

Authors: Klein, C., Schaefer, W., Regula, J.T.

Journal: mAbs

Bibliometrics: Volume 8, Number 6, pages 1010-1020

DOI: http://dx.doi.org/1080/19420862.2016.1197457

The listing originally published as “1) the bevacizumab Fab is replaced by ranibizumab, which exhibits higher affinity for VEGF-A in order to stronger block VEGF-A” on page 1012 of the article should state the following:

1) the bevacizumab Fab is replaced by an anti-VEGF-Fab fragment similar to ranibizumab, which exhibits higher affinity for VEGF-A in order to stronger block VEGF-A